Application of a protein mutant in the construction of recombinant bacteria with high amino acid production

By mutating the 382nd amino acid of the Corynebacterium glutamicum BBD29_15155 gene, a recombinant strain with high amino acid production was constructed, solving the problem of insignificant yield improvement in existing technologies. This resulted in a significant increase in the production of L-glutamic acid and lysine, making it suitable for industrial production.

CN117165500BActive Publication Date: 2026-11-17胡丹
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202110998239.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-08-27
Publication Date
2026-11-17
Estimated Expiration
2041-08-27

AI Technical Summary

Technical Problem

Existing technologies are not very effective in increasing the fermentation yield of glutamic acid and lysine, especially in large-scale fermenters where modifications are limited and the modification methods have failed to effectively increase yield.

Method used

By mutating the 382nd amino acid of the Corynebacterium glutamicum BBD29_15155 gene, especially by replacing alanine with threonine or lysine, a recombinant strain that produces high levels of amino acids was constructed. The strain was then optimized through homologous recombination and strong promoter substitution to improve the accumulation of the target product.

Benefits of technology

It significantly increased the yield of L-glutamic acid and lysine, especially showing a significant improvement in 50L fermenters, laying the foundation for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003234767330000071
    Figure BDA0003234767330000071
  • Figure BDA0003234767330000081
    Figure BDA0003234767330000081
Patent Text Reader

Abstract

This invention relates to the fields of genetic engineering and microbial technology, specifically to the application of a protein mutant in the construction of recombinant bacteria that produce high levels of amino acids. This invention discovers that a mutation at position 382 of the protein encoded by the BBD29_15155 gene plays a significant role in increasing the yield of amino acids (especially L-glutamic acid and lysine). This discovery allows for the construction and screening of microorganisms that produce high levels of amino acids and their derivatives, which is beneficial for increasing the yield of amino acids and their derivatives and lays the foundation for their industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of genetic engineering and microbial technology, specifically to the application of a protein mutant in the construction of recombinant bacteria that produce high levels of amino acids. Background Technology

[0002] Glutamic acid, with the chemical formula C5H9NO4 and a molecular weight of 147.13, is an acidic amino acid. It contains two carboxyl groups and its chemical name is α-aminoglutaric acid.

[0003] Glutamic acid is one of the essential amino acids for nitrogen metabolism in living organisms and plays a vital role in metabolism. L-glutamate is a major component of proteins, and glutamate salts are ubiquitous in nature. Glutamate salts are found in many foods and in the human body; they are both structural amino acids of proteins and peptides and free amino acids. L-glutamate has a stronger flavor.

[0004] Lysine's chemical name is 2,6-diaminohexanoic acid. Lysine is a basic essential amino acid.

[0005] Lysine's catabolism occurs in the liver, where it condenses with ketoglutarate to form yeast amino acids. These yeast amino acids are then converted into L-α-aminohexanoic acid semialdehyde, ultimately producing acetyl-CoA. Unlike other amino acids, lysine does not participate in transamination, and the deamination reaction is irreversible, making lysine's catabolism highly unique. Lysine is a glucogenic and ketogenic amino acid, thus it can participate in the formation of D-glucose, glycogen, and lipids, ultimately generating energy.

[0006] Corynebacterium glutamicum has been the main production bacterium used in the global amino acid fermentation industry for the past forty years. It was first described as a glutamate-producing bacterium by Kinoshita in 1957. Corynebacterium glutamicum belongs to the genus Corynebacterium in the class Actinobacteria of the Gram-positive eubacteria.

[0007] CN 112725253A discloses a method for introducing point mutations into the coding sequence of the BBD29_14900 gene in Corynebacterium or improving its expression, and mentions that the method can increase the fermentation yield of glutamic acid by strains carrying the mutation, but the improvement effect is not obvious, and the modification verification results are limited to 5L fermenters; at the same time, the mutation is only limited to the improvement in glutamic acid. Summary of the Invention

[0008] Corynebacterium glutamicum MHZ-0112-8 (disclosed in CN 105695383A) is known to be a glutamate-producing bacterium for glutamate fermentation and can be used as a control strain in performance verification experiments. During the rejuvenation of MHZ-0112-8, the inventors accidentally discovered that strain G10 exhibited increased glutamate production. Sequencing and analysis revealed that amino acid position 382 of the BBD29_15155 gene in strain G10 was mutated from alanine (A) to threonine (T). Subsequent studies showed that when alanine at position 382 of the protein encoded by the wild-type Corynebacterium glutamicum BBD29_15155 gene was replaced by other amino acids, it helped increase the production of amino acids (especially L-glutamate and lysine).

[0009] Based on the above findings, this invention provides an application of protein mutants in constructing recombinant bacteria that produce high levels of amino acids.

[0010] Specifically, in a first aspect, the present invention provides the use of a protein mutant, or its encoding gene, or biological material containing its encoding gene, in any of the following aspects:

[0011] (1) Constructing microorganisms that produce high levels of amino acids or their derivatives;

[0012] (2) Screening for microorganisms that produce high levels of amino acids or their derivatives;

[0013] Compared to the protein encoded by the wild-type BBD29_15155 gene, the mutant protein has alanine at position 382 replaced by other amino acids.

[0014] Preferably, compared to the protein encoded by the wild-type BBD29_15155 gene, the mutant protein has alanine at position 382 replaced by threonine or lysine.

[0015] More preferably, the alanine at position 382 of the protein mutant is replaced by threonine.

[0016] More preferably, the amino acid sequence of the protein mutant is shown in SEQ ID NO.1.

[0017] Those skilled in the art should understand that adding a tagged protein to the N-terminus or C-terminus of the above-mentioned protein mutant sequence or fusing it with other proteins to form a fusion protein, without changing the activity of the above-mentioned mutant protein itself, the tagged protein or fusion protein is also within the scope of protection of this invention.

[0018] Based on the protein mutants provided above, those skilled in the art can obtain the sequences of the nucleic acids they encode. Due to codon degeneracy, there is more than one nucleic acid sequence encoding the above amino acid sequences; all nucleic acids capable of encoding the above protein mutants are within the scope of protection of this invention.

[0019] Preferably, compared with the wild-type BBD29_15155 gene, the 1144th base of the coding gene of the protein mutant is replaced with adenine instead of guanine.

[0020] As one embodiment of the present invention, the base sequence of the coding gene of the protein mutant (i.e., the BBD29_15155 gene mutant) is shown in SEQ ID NO.2.

[0021] The biological materials mentioned in this invention are expression cassettes, vectors, or host cells.

[0022] The expression cassette is a recombinant nucleic acid molecule obtained by linking elements upstream or downstream of the nucleic acid to drive its transcription and expression.

[0023] The vector may be an expression vector or a cloning vector, including but not limited to plasmid vectors, phage vectors, transposons, etc.

[0024] The host cell includes, but is not limited to, microbial cells.

[0025] Preferably, the amino acids include L-glutamic acid and lysine.

[0026] Preferably, the microorganism is a Corynebacterium genus, and more preferably Corynebacterium glutamicum.

[0027] In practical implementation, the microorganisms can be constructed using the following methods:

[0028] (1) Introduce the expression vector containing the encoding gene of the BBD29_15155 gene mutant into microbial cells;

[0029] (2) Replace the promoter of the gene encoding the BBD29_15155 gene on the chromosome of the microorganism with a strong promoter such as Psod, Ptuf, Psyn, etc.

[0030] Preferably, the original BBD29_15155 gene encoding gene on the chromosome is mutated into the encoding gene of the BBD29_15155 gene mutant.

[0031] The term "mutation" refers to an alteration in the amino acid sequence of a protein-encoding protein caused by the addition, deletion, or substitution of one or more bases in the gene encoding the protein, thereby changing the protein's functional activity. The mutation method can be selected from mutagenesis, site-directed mutagenesis by PCR, and / or homologous recombination. In this invention, homologous recombination is preferred, mutating alanine at position 382 of the protein encoded by the BBD29_15155 gene to threonine.

[0032] When used for the production of the target product, the microorganism is constructed from a starting strain capable of accumulating the target product, wherein the target product includes an amino acid or a derivative thereof, preferably, the amino acid is L-glutamic acid or lysine.

[0033] In a preferred embodiment of the present invention, the microorganism is constructed using Corynebacterium glutamicum, which is capable of accumulating glutamate, as the starting strain.

[0034] Preferably, the starting strain contains one or more of the following characteristics:

[0035] (1) It encodes a mutant yggB protein, which has an A106V point mutation;

[0036] (2) It inhibits the expression of the odhA gene;

[0037] (3) It overexpresses the gdh gene;

[0038] (4) It overexpresses the gltA gene.

[0039] As a preferred embodiment, the present invention further provides a recombinant bacterium, which is constructed from Corynebacterium glutamicum MHZ-0112-8 with preservation number CGMCC No.11941 as the starting strain; it expresses a protein mutant; or, it contains the coding gene of the protein mutant; the protein mutant or its coding gene is as described above.

[0040] The Corynebacterium glutamicum MHZ-0112-8 has been disclosed in CN 105695383A, and its classification name is Corynebacterium glutamicum. It was deposited on December 25, 2015, at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 11941.

[0041] As a preferred embodiment, the present invention further provides a recombinant bacterium, which is constructed from Corynebacterium glutamicum MHZ-0912-6 with accession number CGMCC No.11942 as the starting strain; it expresses a protein mutant; or, it contains the coding gene of the protein mutant; the protein mutant or its coding gene is as described above.

[0042] The Corynebacterium glutamicum MHZ-0912-6 has been disclosed in CN 105734004A, and its classification name is Corynebacterium glutamicum. It was deposited on December 25, 2015, at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 11942.

[0043] In practice, a recombinant plasmid carrying the gene encoding the BBD29_15155 gene mutant can be introduced into the starting strain.

[0044] Preferably, the recombinant plasmid is a plasmid that can undergo homologous recombination in bacterial cells, and the coding gene of the BBD29_15155 gene mutant on the plasmid is exchanged with a homologous gene on the chromosome.

[0045] In a preferred embodiment, the method for constructing the recombinant bacteria includes:

[0046] (1) Construct a recombinant plasmid containing the gene encoding the BBD29_15155 gene mutant;

[0047] (2) Transform the recombinant plasmid into the starting strain and screen the transformants using a selective medium containing antibiotics;

[0048] (3) Screening for recombinant microorganisms that have undergone the target mutation in positive transformants.

[0049] Fourthly, the present invention also provides the application of the aforementioned microorganisms in the production of amino acids and their derivatives.

[0050] Preferably, the amino acids include L-glutamic acid and lysine.

[0051] The microorganisms of the present invention can increase the yield of amino acids when producing amino acid derivatives, thereby increasing the yield of the corresponding amino acid derivatives.

[0052] Furthermore, the present invention also provides a method for producing L-glutamic acid, comprising: culturing the microorganisms to produce, accumulate and collect L-glutamic acid.

[0053] The preferred microorganism was constructed using Corynebacterium glutamicum MHZ-0112-8, with preservation number CGMCC No.11941, as the starting strain.

[0054] The preferred fermentation medium comprises the following components: glucose 50-60 g / L, ammonium sulfate 10-20 g / L, KH2PO4 0.5-1.5 g / L, MgSO4·7H2O 0.2-0.5 g / L, FeSO4·7H2O 0.05-0.15 mg / L, MnSO4·5H2O 0.8-1.2 mg / L, VB1 150-250 μg / L, biotin 250-350 μg / L, soybean hydrolysate 0.3-0.6 g / L, pH 7.2-7.5;

[0055] Alternatively, the fermentation medium used may include the following components: glucose 15-25 g / L, corn steep liquor 15-25 g / L, betaine hydrochloride 0.1-0.3 g / L, K₂HPO₄ 6-8 g / L, MgSO₄·7H₂O 1-2 g / L, V B1 150-250μg / L, VH 550-650μg / L, FeSO4·7H2O 25-35mg / L, MnSO4·H2O 25-35mg / L, urea 0.4-0.7g / L, pH 7.2-7.5.

[0056] In a preferred embodiment, the fermentation medium comprises: glucose 60 g / L, ammonium sulfate 15 g / L, KH₂PO₄ 1.0 g / L, MgSO₄·7H₂O 0.4 g / L, FeSO₄·7H₂O 1.0 mg / L, MnSO₄·5H₂O 1.0 mg / L, V B1 200 μg / L, biotin 300 μg / L, soybean hydrolysate 0.48 g / L, pH 7.2-7.5.

[0057] Furthermore, the present invention also provides a method for producing lysine, comprising: culturing the microorganisms to produce, accumulate and collect lysine.

[0058] The preferred microorganism was constructed using Corynebacterium glutamicum MHZ-0912-6, with preservation number CGMCC No.11942, as the starting strain.

[0059] The preferred fermentation medium comprises the following components: glucose 55-65 g / L, (NH4)2SO4 22-28 g / L, KH2PO4 1.5-2.5 g / L, MgSO4·7H2O 0.8-1.2 g / L, yeast extract 8-12 g / L, CaCO3 20-30 g / L, pH 6.8-7.2.

[0060] In specific implementation schemes, when using the microorganisms described above to produce amino acids and their derivatives, the microorganisms are generally inoculated onto slant culture medium for slant culture, the bacterial growth on the slant culture medium is picked and inoculated onto seed culture medium for seed culture, and then the seed culture is transferred into fermentation medium for fermentation.

[0061] Preferably, the slant culture medium is composed of: 5 g / L yeast extract, 10 g / L beef extract, 10 g / L peptone, 10 g / L sodium chloride, 2.5 g / L agar powder, and pH 7.0-7.2.

[0062] Preferably, the seed culture medium is composed of: glucose 25 g / L, urea 3.0 g / L, K2HPO4·3H2O 2.2 g / L, MgSO4·7H2O 0.9 g / L, corn steep liquor 33 mL / L, soybean meal hydrolysate 22 mL / L, and pH 7.0-7.2.

[0063] Preferably, the seed culture is carried out at 31.5℃ and 220 rpm with shaking until the mid-to-late logarithmic growth stage, and the culture time is 10-14 hours.

[0064] Preferably, the fermentation is carried out at 31.5°C with shaking at 220 rpm for 12-20 hours.

[0065] Based on the above technical solution, the beneficial effects of the present invention are as follows:

[0066] This invention has discovered that the mutation at position 382 of the protein encoded by the BBD29_15155 gene plays a prominent role in increasing the yield of amino acids (especially L-glutamic acid and lysine). When the modified strain was scaled up to a 50L fermenter to verify the yield, it still showed a significant increase. This discovery can be used to construct and screen microorganisms that produce high levels of amino acids and their derivatives, which is beneficial to increasing the yield of amino acids and their derivatives and lays the foundation for their industrial production. Detailed Implementation

[0067] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the invention.

[0068] The primer names and sequences involved in the examples are shown in Table 1 (SEQ ID NO.3-14 from top to bottom).

[0069] Table 1 Primer sequences

[0070]

[0071]

[0072] The strains involved in the examples are as follows:

[0073] The originating strain, Corynebacterium glutamicum MHZ-0112-8, has been disclosed in CN 105695383A. Its classification name is Corynebacterium glutamicum. It was deposited on December 25, 2015, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 11941.

[0074] The originating strain, Corynebacterium glutamicum MHZ-0912-6, has been disclosed in CN 105734004A. Its classification name is Corynebacterium glutamicum. It was deposited on December 25, 2015, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 11942.

[0075] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.

[0076] Example 1: Construction of recombinant plasmid pK18-BBD29_15155(A382T)

[0077] Primers were designed based on the sequence of the gene NO:BBD29_15155 from the NCBI database, and the primer sequences are shown in Table 1. Using Phusion superfidelity polymerase (New England BioLabs), primer pairs BBD29_15155-UP-1F / BBD29_15155-UP-1R and BBD29_15155-DN-2F / BBD29_15155-DN-2R were used as primer pairs. Recombinant fragments were prepared using the genome of Corynebacterium glutamicum MHZ-0112-08 as a template. The PCR program was: 98℃ denaturation for 10 s, 55℃ annealing for 20 s, 72℃ extension for 15 s, 30 cycles, followed by a final extension at 72℃ for 10 min. The obtained fragment was purified using an agarose gel extraction kit (Tiangen). Then, using BBD29_15155-UP-1F / BBD29_15155-DN-2R as primers and upstream and downstream homologous arms as templates, recombinant fragments were prepared. The PCR program was: 98℃ denaturation for 10 s, 50℃ annealing for 20 s, 72℃ extension for 30 s, 30 cycles, followed by a final extension at 72℃ for 10 min. The obtained recombinant fragment was purified and recovered using an agarose gel extraction kit (Tiangen) and stored at -20℃ for later use. pK18-mobsacB was digested with BamHI / HindIII restriction endonucleases. The amplified BBD29_15155-UP / BBD29_15155-DN fragment was mixed with the double-digested vector at a certain ratio using the ClonExpress MultiS One Step Cloning Kit (Novizan Biotechnology Co., Ltd.). After mixing, the mixture was placed in a metal bath (Ginkgo Biloba Biotechnology Co., Ltd.) at 37°C for 30 min. After the reaction, the cells were transformed into Trans1T1 competent cells (TransGen Biotech). Kanamycin-resistant clones were picked, and positive clones with pK18mobsacB inserted were identified by BamHI / HindIII digestion. The insertion was further confirmed by sequencing (Invitrogen). The resulting plasmid was named pK18-BBD29_15155 (A382T).

[0078] Example 2: Introducing a point mutation in the BBD29_15155(A382T) gene into strain MHZ-0112-8

[0079] MHZ-0112-8 competent cells were prepared according to the classic method for Corynebacterium glutamicum (C. glutamicum Handbook, Charter 23), and the recombinant plasmid pK18-BBD29_15155 was applied. A382TThe cells were transformed into *Corynebacterium glutamicum* MHZ-0112-8 competent cells by electroporation, and exchange recombinants were selected on selective medium containing 15 mg / L kanamycin. Colony PCR was performed using Fast Taq DNA polymerase (TransGen Biotech) with primer pairs BBD29_15155-UP-1F / P85, P82 / BBD29_15155-DN-2R to identify the recombinants. R Cloning was performed using PCR parameters: 94℃ for 30 seconds, 55℃ for 30 seconds, 72℃ for 30 seconds, for a total of 30 cycles, followed by a 72℃ extension for 10 minutes. Clones amplifying fragments of 1226 bp and 1115 bp using the two primer pairs were considered positive clones. The selected positive clones were inoculated into antibiotic-free BHI medium and cultured for 12 hours. The bacterial suspensions were then diluted 100 and 1000 times and plated onto solid BHI medium containing 10% sucrose, and cultured for 36 hours. The selected strains were further subjected to kanamycin resistance phenotype verification. S The recombinants were verified using the identification primer pair BBD29_15155-F / BBD29_15155-DN-2R. By exploring the annealing temperature, recombinants containing point mutations were obtained. The positive recombinants were amplified and sequenced using ID-F / ID-R. The correct recombinant was 1244 bp in length, and the correctly sequenced strain was named MHZ-0112-29.

[0080] Example 3: Validation of the glutamic acid production performance of the MHZ-0112-29 mutant strain

[0081] The recombinant Corynebacterium glutamicum constructed in Example 2 was fermented to verify its glutamic acid production performance, as detailed below:

[0082] The strain, frozen in glycerol tubes at -80℃, was inoculated into the above-mentioned slant medium for activation. After culturing at 31.5℃ for 24 h, bacterial growth occurred. Bacterial growth was picked from the freshly activated slant and inoculated into the above-mentioned seed culture medium. The culture was then incubated at 31.5℃ with shaking at 220 rpm until the mid-to-late logarithmic growth stage, for 12 h, to obtain the seed culture. A 10% inoculum of this seed culture was inoculated into a 500 ml shake flask containing 20 ml of fermentation medium and incubated at 31.5℃ with shaking at 220 rpm for 16 h. After complete glucose consumption, the concentration of L-glutamic acid accumulated in the culture medium was determined by HPLC.

[0083] The culture medium formula is as follows:

[0084] Slant culture medium: yeast powder 5.0 g / L, beef extract 10 g / L, peptone 10 g / L, sodium chloride 10 g / L, agar powder 2.5 g / L, pH 7.0-7.2, sterilized at 121℃ and 0.1 MPa for 30 min;

[0085] Seed culture medium: glucose 25 g / L, urea 3.0 g / L, K2HPO4·3H2O 2.2 g / L, MgSO4·7H2O 0.9 g / L, corn steep liquor 33 mL / L, soybean meal hydrolysate 22 mL / L, pH 7.0-7.2, sterilized at 121℃ and 0.1 MPa for 15 min;

[0086] Fermentation medium: glucose 60 g / L, ammonium sulfate 15 g / L, KH₂PO₄ 1.0 g / L, MgSO₄·7H₂O 0.4 g / L, FeSO₄·7H₂O 1.0 mg / L, MnSO₄·5H₂O 1.0 mg / L, V B1 200 μg / L of biotin, 300 μg / L of soybean hydrolysate, 0.48 g / L of sodium bicarbonate, adjusted to pH 7.2-7.5 with NaOH, sterilized at 121℃ and 0.1 MPa for 15 min, and then 1.0 g of heat-sterilized calcium carbonate was added.

[0087] Table 2. Detection of glutamic acid content in mutant strains

[0088] strains <![CDATA[OD 600 (×100)]]> Glu (g / L) Conversion rate % MHZ-0112-8 0.425±0.015 33.2±0.10 55.3±0.20 MHZ-0112-29 0.401±0.028 35.7±0.13 59.5±0.26

[0089] The results are shown in Table 2 (OD). 600 The turbidity of the culture medium diluted 100 times at 600 nm is used to represent cell mass, and Glu (g / L) represents the amount of accumulated L-glutamate. In MHZ-0112-29, the amino acid at position 382 of the BBD29_15155 gene was mutated from alanine (A) to threonine (T), i.e., GCA was mutated to ACA. This increased the glutamate concentration from 33.2 g / L to 35.7 g / L, resulting in a 4.2% increase in conversion rate. The results indicate that the BBD29_15155 gene mutant of this invention can improve glutamate synthesis.

[0090] Example 4: Construction of recombinant plasmid pK18-BBD29_15155(A382K)

[0091] Primers were designed based on the sequence of the gene NO:BBD29_15155 from the NCBI database, and the primer sequences are shown in Table 1. Using Phusion superfidelity polymerase (New England BioLabs), primer pairs BBD29_15155-UP-1F / BBD29_15155-A382K-UP-1R and BBD29_15155-A382K-DN-2F / BBD29_15155-DN-2R were used as primer pairs. Recombinant fragments were prepared using the genome of Corynebacterium glutamicum MHZ-0112-08 as a template. The PCR program was: 98℃ denaturation for 10 s, 55℃ annealing for 20 s, 72℃ extension for 15 s, 30 cycles, followed by a final extension at 72℃ for 10 min. The obtained fragment was purified using an agarose gel extraction kit (Tiangen). Then, using BBD29_15155-UP-1F / BBD29_15155-DN-2R as primers and upstream and downstream homologous arms as templates, recombinant fragments were prepared. The PCR program was: 98℃ denaturation for 10 s, 50℃ annealing for 20 s, 72℃ extension for 30 s, 30 cycles, followed by a final extension at 72℃ for 10 min. The obtained recombinant fragment was purified and recovered using an agarose gel extraction kit (Tiangen) and stored at -20℃ for later use. pK18-mobsacB was digested with BamHI / HindIII restriction endonucleases. The amplified BBD29_15155-UP / BBD29_15155-DN fragment was mixed with the double-digested vector at a certain ratio using the ClonExpress MultiS One Step Cloning Kit (Novizan Biotechnology Co., Ltd.). After mixing, the mixture was placed in a metal bath (Ginkgo Biloba Biotechnology Co., Ltd.) at 37°C for 30 min. After the reaction, the cells were transformed into Trans1T1 competent cells (TransGenBiotech). Kanamycin-resistant clones were picked, and positive clones with pK18mobsacB inserted were identified by BamHI / HindIII digestion. The insertion was further confirmed by sequencing (Invitrogen). The resulting plasmid was named pK18-BBD29_15155 (A382K).

[0092] Example 5: Introducing a point mutation in the BBD29_15155(A382K) gene into strain MHZ-0112-8

[0093] MHZ-0112-8 competent cells were prepared according to the classic method for Corynebacterium glutamicum (C. glutamicum Handbook, Charter 23), and the recombinant plasmid pK18-BBD29_15155 was applied. A382KThe cells were transformed into *Corynebacterium glutamicum* MHZ-0112-8 competent cells by electroporation, and exchange recombinants were selected on selective medium containing 15 mg / L kanamycin. Colony PCR was performed using Fast Taq DNA polymerase (TransGen Biotech) with primer pairs BBD29_15155-UP-1F / P85, P82 / BBD29_15155-DN-2R to identify the recombinants. R Cloning was performed using PCR parameters: 94℃ for 30 seconds, 55℃ for 30 seconds, 72℃ for 30 seconds, for a total of 30 cycles, followed by a 72℃ extension for 10 minutes. Clones amplifying fragments of 1226 bp and 1115 bp using the two primer pairs were considered positive clones. The selected positive clones were inoculated into antibiotic-free BHI medium and cultured for 12 hours. The bacterial suspensions were then diluted 100 and 1000 times and plated onto solid BHI medium containing 10% sucrose, and cultured for 36 hours. The selected strains were further subjected to kanamycin resistance phenotype verification. S The recombinants were identified using the identification primer pair -BBD29_15155-A382K-F / BBD29_15155-DN-2R to verify the point mutation recombinants. By exploring the annealing temperature, recombinants containing point mutations were obtained. The obtained positive recombinants were amplified and sequenced using ID-F / ID-R. The correct recombinant was 1244 bp in length, and the correctly sequenced strain was named MHZ-0112-30.

[0094] Example 6: Validation of the glutamic acid production performance of the MHZ-0112-30 mutant strain

[0095] The recombinant Corynebacterium glutamicum constructed in Example 5 was fermented to verify its glutamic acid production performance, as detailed below:

[0096] The strain, frozen in glycerol tubes at -80℃, was inoculated into the above-mentioned slant medium for activation. After culturing at 31.5℃ for 24 h, bacterial growth occurred. Bacterial growth was picked from the freshly activated slant and inoculated into the above-mentioned seed culture medium. The culture was then incubated at 31.5℃ with shaking at 220 rpm until the mid-to-late logarithmic growth stage, for 12 h, to obtain the seed culture. A 10% inoculum of this seed culture was inoculated into a 500 ml shake flask containing 20 ml of fermentation medium and incubated at 31.5℃ with shaking at 220 rpm for 16 h. After complete glucose consumption, the concentration of L-glutamic acid accumulated in the culture medium was determined by HPLC.

[0097] The culture medium formula is as follows:

[0098] Slant culture medium: yeast powder 5.0 g / L, beef extract 10 g / L, peptone 10 g / L, sodium chloride 10 g / L, agar powder 2.5 g / L, pH 7.0-7.2, sterilized at 121℃ and 0.1 MPa for 30 min;

[0099] Seed culture medium: glucose 25 g / L, urea 3.0 g / L, K2HPO4·3H2O 2.2 g / L, MgSO4·7H2O 0.9 g / L, corn steep liquor 33 mL / L, soybean meal hydrolysate 22 mL / L, pH 7.0-7.2, sterilized at 121℃ and 0.1 MPa for 15 min;

[0100] Fermentation medium: glucose 60 g / L, ammonium sulfate 15 g / L, KH₂PO₄ 1.0 g / L, MgSO₄·7H₂O 0.4 g / L, FeSO₄·7H₂O 1.0 mg / L, MnSO₄·5H₂O 1.0 mg / L, V B1 200 μg / L of biotin, 300 μg / L of soybean hydrolysate, 0.48 g / L of sodium bicarbonate, adjusted to pH 7.2-7.5 with NaOH, sterilized at 121℃ and 0.1 MPa for 15 min, and then 1.0 g of heat-sterilized calcium carbonate was added.

[0101] Table 3. Detection of glutamic acid content in mutant strains.

[0102] strains <![CDATA[OD 600 (×100)]]> Glu (g / L) Conversion rate % MHZ-0112-8 0.425±0.015 33.2±0.10 55.3±0.20 MHZ-0112-30 0.390±0.017 35.5±0.13 59.2±0.18

[0103] The results are shown in Table 3 (OD 600 The turbidity of the culture medium diluted 100 times at 600 nm is used to represent cell mass, and Glu (g / L) represents the amount of accumulated L-glutamate. In MHZ-0112-30, the amino acid at position 382 of BBD29_15155 was mutated from alanine (A) to lysine (K), i.e., GCA was mutated to AAA. This resulted in an increase in glutamate concentration from 33.2 g / L to 36.3 g / L, with a 3.9% increase in conversion rate. The results indicate that the BBD29_15155 mutant of this invention can improve glutamate synthesis.

[0104] Example 7: Introducing a point mutation in the BBD29_15155(A382T) gene into strain MHZ-0912-6

[0105] MHZ-0912-6 competent cells were prepared according to the classic method for *Corynebacterium glutamicum* (*C. glutamicum* Handbook, Charter 23). The recombinant plasmid pK18-BBD29_15155(A382T) was electroporated into *Corynebacterium glutamicum* MHZ-0912-6 competent cells. Exchange recombinants were selected on selective medium containing 15 mg / L kanamycin. Colony PCR was performed using Fast Taq DNA polymerase (TransGen Biotech) with primer pairs BBD29_15155-1F / P85 and P82 / BBD29_15155-2R to identify the kanamycin.R Cloning was performed using PCR parameters: 94℃ for 30 seconds, 50℃ for 30 seconds, 72℃ for 35 seconds, for a total of 30 cycles, followed by a complete extension at 72℃ for 10 minutes. Clones amplifying fragments of 1226 bp and 1115 bp using the two primer pairs were considered positive clones. The selected positive clones were inoculated into antibiotic-free BHI medium and cultured for 12 hours. The bacterial suspensions were then diluted 100 and 1000 times and plated onto solid BHI medium containing 10% sucrose, and cultured for 36 hours. The selected strains were further subjected to kanamycin resistance phenotype verification. S The recombinants were verified using the identification primer pair BBD29_15155-F / BBD29_15155-2R. By exploring the annealing temperature, recombinants containing point mutations were obtained. The positive recombinants were amplified and sequenced using BBD29_15155-ID-F / BBD29_15155-ID-R. The correct recombinant was 1244 bp in length, and the correctly sequenced strain was named MHZ-0912-8.

[0106] Example 8: Validation of the lysine production performance of the MHZ-0912-8 mutant strain.

[0107] The recombinant Corynebacterium glutamicum constructed in Example 7 was fermented to verify its lysine production performance, as detailed below:

[0108] The strain, frozen in glycerol tubes at -80℃, was inoculated into the above-mentioned slant medium for activation. After culturing at 31.5℃ for 24 hours, bacterial growth occurred. Bacterial growth was picked from the freshly activated slant and inoculated into the above-mentioned seed culture medium. The culture was then incubated at 31.5℃ with shaking at 220 rpm until the mid-to-late logarithmic growth stage, for 12 hours, to obtain the seed culture. A 10% inoculum of this seed culture was inoculated into a 500 ml shake flask containing 20 ml of fermentation medium and incubated at 31.5℃ with shaking at 220 rpm for 16 hours. After complete glucose consumption, the concentration of lysine accumulated in the culture medium was determined by HPLC.

[0109] The culture medium formula is as follows:

[0110] Slant culture medium: yeast powder 5.0 g / L, beef extract 10 g / L, peptone 10 g / L, sodium chloride 10 g / L, agar powder 2.5 g / L, pH 7.0-7.2, sterilized at 121℃ and 0.1 MPa for 30 min;

[0111] Seed culture medium: glucose 25 g / L, urea 3.0 g / L, K2HPO4·3H2O 2.2 g / L, MgSO4·7H2O 0.9 g / L, corn steep liquor 33 mL / L, soybean meal hydrolysate 22 mL / L, pH 7.0-7.2, sterilized at 121℃ and 0.1 MPa for 15 min;

[0112] Fermentation medium: glucose 60g / L, (NH4)2SO4 25g / L, KH2PO4 2.0g / L, MgSO4·7H2O 1.0g / L, yeast powder 10g / L, CaCO3 30g / L, adjust pH to 7.0 with NaOH, sterilize at 121℃ and 0.1MPa for 15min.

[0113] Table 4. Detection of lysine content in mutant strains

[0114] strains OD600(×100) Lys(g / L) Conversion rate % CGMCC No. 11942 0.453±0.16 8.1±0.20 13.5±0.15 MHZ-0912-8 0.424±0.11 9.9±0.22 16.5±0.12

[0115] The results are shown in Table 4. OD600 represents the turbidity of the culture medium diluted 100 times at 600 nm, indicating cell mass, and Lys (g / L) represents the amount of accumulated L-lysine. In MHZ-0912-8, the amino acid at position 382 of BBD29_15155 was mutated from alanine (A) to threonine (T), i.e., GCA mutated to ACA. This resulted in an increase in lysine concentration from 8.1 g / L to 9.9 g / L, representing a 3% increase in lysine conversion. This indicates that the BBD29_15155 mutant of this invention can improve lysine synthesis.

[0116] Example 9: Performance Verification of Glutamic Acid Production by Mutant Strains

[0117] The recombinant Corynebacterium glutamicum constructed in Examples 2 and 5 were subjected to 50L scale-up fermentation to verify their glutamic acid production performance, as detailed below:

[0118] The strain, frozen in -80℃ glycerol tubes, was activated by inoculating it onto slant agar. After culturing at 31.5℃ for 24 hours, mycelial growth occurred. Mycelial growth was picked from the freshly activated slant and inoculated into the secondary seed culture medium described below. The medium was then cultured at 31.5℃ with shaking at 150 rpm until the mid-to-late logarithmic growth phase, for 10 hours, to obtain the seed culture. This seed culture was then inoculated into tertiary seed culture medium at a 10% inoculum. The culture was then inoculated into a 5L automated fermenter at 30℃, pH 7.0, and dissolved oxygen 20% for 12 hours until the logarithmic growth phase. Finally, a 10% inoculum was added to fermentation medium containing... In a 50L automated fermenter containing the culture medium, the initial culture temperature was controlled at 30℃. When the fermentation broth was diluted 20 times and the OD600 value was 0.35, the temperature was increased to 37℃ within 5 minutes. Appropriate air was introduced, and the stirring speed was adjusted appropriately. Dissolved oxygen was controlled using a staged oxygen supply mode: 20% for 0-10h and 5% for 10-32h. The pH was controlled at 7.0-7.2 by automatically adding ammonia water. Foaming was eliminated by adding an appropriate amount of foaming agent, and residual sugar was controlled at 1.5% by adding a glucose solution with a concentration of 800g / L. Fermentation was stopped after 32h.

[0119] The culture medium formula is as follows:

[0120] Secondary seed culture medium: glucose 25 g / L, urea 3 g / L, K2HPO4·3H2O 2.2 g / L, MgSO4·7H2O 0.9 g / L, corn steep liquor 33 mL / L, soybean meal hydrolysate 22 mL / L, pH 7.0-7.2, sterilized at 121℃ and 0.1 MPa for 15 min;

[0121] Tertiary seed culture medium: glucose 15g / L, corn steep liquor 20g / L, K2HPO4 3g / L, MgSO4·7H2O 1g / L, VB1 200μg / L, DL-methionine 50μg / L, FeSO4·7H2O 2mg / L, MnSO4·H2O 2mg / L, urea 0.55g / L (disintegrated), pH 7.0-7.2, sterilized at 121℃ for 15min;

[0122] Formula for 50L fermentation medium: glucose 20g / L, corn steep liquor 20g / L, betaine hydrochloride 0.25g / L, K2HPO4 7.5g / L, MgSO4·7H2O 1.5g / L, VB1 200μg / L, VH 600μg / L, FeSO4·7H2O 30mg / L, MnSO4·H2O 30mg / L, urea 0.55g / L, pH 7.2-7.5.

[0123] Table 5 Results of glutamic acid fermentation experiments with mutant strains

[0124] strains OD600(×200) Glu (g / L) Conversion rate % MHZ-0112-8 52.3±0.027 177.9±0.4 61.5±0.12 MHZ-0112-29 47.7±0.018 182.6±0.2 63.4±0.15 MHZ-0112-30 48.5±0.011 181.1±0.2 62.6±0.04

[0125] The results are shown in Table 5. OD600 is the turbidity of the culture medium diluted 200 times at 600 nm, representing cell mass. Glu (g / L) represents the amount of accumulated L-glutamate. In MHZ-0112-29, the amino acid at position 382 of BBD29_15155 was mutated from alanine (A) to threonine (T), increasing the glutamate content from 177.9 g / L to 182.6 g / L, and improving the conversion rate by 1.9%. In MHZ-0112-30, the amino acid at position 382 of BBD29_15155 was mutated from alanine (A) to lysine (K), increasing the glutamate content from 177.9 g / L to 181.1 g / L.

[0126] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention. sequence list <110> Hu Dan <120> Application of a protein mutant in the construction of recombinant bacteria with high amino acid production <130> KHP211117893.3 <160> 14 <170> SIPOSequenceListing 1.0 <210> 1 <211> 508 <212> PRT <213> Artificial Sequence <400> 1 Met Thr Asp Ile Lys Ala Thr Ser Ser Thr Ser Ala Thr Thr Ala Pro 1 5 10 15 Thr Ala Gly Arg Pro Ala Arg Arg Leu Gly Gln Ile Ser Leu Val Ala 20 25 30 Cys Leu Gly Gly Leu Leu Phe Gly Tyr Asp Thr Gly Val Ala Asn Gly 35 40 45 Ala Glu Gly His Met Ala Gln Glu Leu Gly Leu Asn Val Leu Gln Leu 50 55 60 Gly Val Val Ile Ser Ser Leu Val Phe Ala Ala Ala Phe Gly Ala Leu 65 70 75 80 Phe Ala Gly Arg Ile Ser Asp Glu Ile Gly Arg Arg Lys Ala Ile Ile 85 90 95 Thr Leu Ser Val Leu Phe Phe Leu Gly Ser Ile Leu Val Val Phe Ser 100 105 110 Pro Ala Gly Glu Leu Gly Gln Phe Tyr Gly Pro Gly Phe Ala Thr Leu 115 120 125 Val Thr Gly Arg Ile Met Leu Gly Leu Ala Val Gly Gly Ala Ser Thr 130 135 140 Val Val Pro Val Tyr Leu Ala Glu Leu Ala Pro Leu Glu Ile Arg Gly 145 150 155 160 Ser Leu Thr Gly Arg Asn Glu Leu Ala Ile Val Thr Gly Gln Leu Leu 165 170 175 Ala Phe Val Ile Asn Ala Leu Ile Ala Val Thr Leu His Gly Val Ile 180 185 190 Asp Gly Ile Trp Arg Ile Met Phe Ala Val Cys Ala Leu Pro Ala Val 195 200 205 Ala Leu Phe Leu Gly Met Leu Arg Met Pro Glu Ser Pro Arg Trp Leu 210 215 220 Val Asn Gln Gly Arg Tyr Asp Asp Ala Arg Arg Val Met Glu Thr Val 225 230 235 240 Arg Thr Pro Glu Arg Ala Lys Val Glu Met Asp Glu Ile Ile Ala Val 245 250 255 His Ser Glu Asn Asn Ala Ala Leu Pro Gly Val Lys Gln Ser Ala Gly 260 265 270 Gln Ala Ser Gly Gln Val Ser Ser Lys His Thr His Met Ser Ile Gly 275 280 285 Glu Val Leu Ser Asn Lys Trp Leu Val Arg Leu Leu Ile Ala Gly Ile 290 295 300 Gly Val Ala Val Ala Gln Gln Leu Thr Gly Ile Asn Ala Ile Met Tyr 305 310 315 320 Tyr Gly Thr Arg Val Leu Glu Glu Ser Gly Met Ser Ala Glu Met Ala 325 330 335 Val Val Ala Asn Ile Ala Phe Gly Ala Val Ala Val Ile Gly Gly Leu 340 345 350 Ile Ala Leu Arg Asn Met Asp Arg Leu Asp Arg Arg Thr Thr Phe Ile 355 360 365 Ile Gly Leu Ser Leu Thr Thr Thr Phe His Leu Leu Ile Thr Ala Ala 370 375 380 Gly Thr Leu Leu Pro Glu Gly Asn Ser Ile Arg Pro Phe Ala Ile Met 385 390 395 400 Ile Leu Val Val Gly Phe Val Leu Ser Met Gln Thr Phe Leu Asn Val 405 410 415 Ala Val Trp Val Trp Leu Ala Glu Ile Phe Pro Val Arg Met Lys Gly 420 425 430 Ile Gly Thr Gly Ile Ser Val Phe Cys Gly Trp Gly Ile Asn Gly Val 435 440 445 Leu Ala Leu Phe Phe Pro Ala Leu Val Ser Gly Val Gly Ile Thr Phe 450 455 460 Ser Phe Leu Ile Phe Ala Val Val Gly Val Ile Ala Leu Ala Phe Val 465 470 475 480 Thr Lys Phe Val Pro Glu Thr Arg Gly Arg Ser Leu Glu Glu Leu Asp 485 490 495 His Ala Ala Phe Thr Gly Gln Ile Phe Lys Lys Ala 500 505 <210> 2 <211> 1527 <212> DNA <213> Artificial Sequence <400> 2 atgacggaca tcaaggccac atcaagtaca tcggccacta cagcaccaac agcaggccga 60 ccagcgcgtc gacttggaca aatctccctc gtcgcctgtc tcggcggact cctcttcggc 120 tatgacaccg gtgtcgccaa cggcgccgaa ggccacatgg cacaagaact cggactcaac 180 gtgctgcaac tcggcgttgt catcagttca ctggttttcg ctgcagcctt tggtgcgctg 240 ttcgctgggc gtatctcgga cgaaatcggg cgtcgaaaag caattatcac tttgtccgtg 300 ctgttcttcc tcggatcaat cctcgtcgta ttctcccccg ccggtgagct ggggcagttc 360 tacggaccag gatttgccac cttggtcacc gggcgcatca tgttgggtct cgcggttggc 420 ggcgcctcca cagtagttcc ggtgtacctc gctgaactcg caccactaga aatccgcggc 480 tccctgaccg gccgaaacga gcttgctatc gtcaccggcc agctgcttgc cttcgtgatc 540 aacgcgctta tcgccgtcac cctacacgga gttattgatg gaatctggcg catcatgttc 600 gccgtctgtg ccctccctgc cgtcgccctc ttcctcggca tgctgcggat gccggaatca 660 ccacgctggc tggtcaacca ggggcgttac gacgacgccc gccgcgtcat ggagactgtc 720 cgtacccctg agcgtgcgaa agtcgaaatg gatgaaatca tcgcggtgca ctctgaaaac 780 aatgcggcac ttcctggtgt taagcagtct gcgggccagg cttcaggcca ggtttctagc 840 aagcacaccc acatgtccat cggcgaagtc ctcagcaaca aatggctggt tcgtctgctc 900 atcgccggca tcggtgttgc agttgcccag cagctcaccg gcatcaacgc catcatgtac 960 tacggaaccc gcgtcctcga ggaatccggc atgagcgcag aaatggctgt ggttgccaac 1020 attgctttcg gtgccgttgc cgtcatcggt ggactgatcg cactgcgcaa catggaccgc 1080 ctggatcgcc gcaccacctt catcatcggc ctgtcactga ccaccacctt ccaccttttg 1140 atcacagctg ctggcactct ccttccagaa ggtaactcca ttcgaccatt cgccatcatg 1200 atccttgttg ttgggttcgt gctctccatg cagaccttcc tcaacgttgc agtgtgggtg 1260 tggctggcgg aaatcttccc agtccgaatg aagggtatcg gcaccggtat ctcggtattc 1320 tgcggttggg gcatcaatgg cgtcctagcg ttgttcttcc cagcactggt ctccggcgtg 1380 ggtatcacct tctccttcct tatcttcgca gtcgtcggag tcattgccct ggcgttcgtc 1440 accaagtttg ttcctgaaac ccgtggccgc tcacttgaag aactcgacca cgcagcattc 1500 accggccaga tcttcaagaa ggcttaa 1527 <210> 3 <211> 41 <212> DNA <213> Artificial Sequence <400> 3 gagctcggta cccggggatc ctgcggatgc cggaatcacc a 41 <210> 4 <211> 32 <212> DNA <213> Artificial Sequence <400> 4 gcagctgtga tcaaaaggtg gaaggtggtg gt 32 <210> 5 <211> 31 <212> DNA <213> Artificial Sequence <400> 5 caccttttga tcacagctgc tggcactctc c 31 <210> 6 <211> 42 <212> DNA <213> Artificial Sequence <400> 6 acgacggcca gtgccaagct tatgactttc tgtggaaggg tg 42 <210> 7 <211> twenty four <212> DNA <213> Artificial Sequence <400> 7 ccagcagctt tgatcaaaag gtgg 24 <210> 8 <211> 26 <212> DNA <213> Artificial Sequence <400> 8 cttttgatca aagctgctgg cactct 26 <210> 9 <211> twenty three <212> DNA <213> Artificial Sequence <400> 9 caccaccttc caccttttga tca 23 <210> 10 <211> twenty two <212> DNA <213> Artificial Sequence <400> 10 ccaccttcca ccttttgatc aa 22 <210> 11 <211> twenty one <212> DNA <213> Artificial Sequence <400> 11 ggccagctgc ttgccttcgt g 21 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <400> 12 gaggccacct tatgggcgat 20 <210> 13 <211> twenty three <212> DNA <213> Artificial Sequence <400> 13 ctcgtatgtt gtgtggaatt gtg 23 <210> 14 <211> 20 <212> DNA <213> Artificial Sequence <400> 14 cgccctgagt gcttgcggca 20

Claims

1. The use of a protein mutant or its encoding gene in any of the following aspects: (1) Constructing a Corynebacterium glutamicum that produces high levels of L-glutamic acid and / or lysine; (2) Screening for Corynebacterium glutamicum that produce high levels of L-glutamic acid and / or lysine; Compared to the protein encoded by the wild-type BBD29_15155 gene, the mutant protein has alanine at position 382 replaced by threonine or lysine. The amino acid sequence of the protein encoded by the wild-type BBD29_15155 gene is shown in SEQ ID NO.

1.

2. The application according to claim 1, characterized in that, Compared to the wild-type BBD29_15155 gene, the protein mutant has adenine replaced by guanine at position 1144 of its coding gene.

3. The application according to claim 2, characterized in that, The base sequence of the gene encoding the protein mutant is shown in SEQ ID NO.

2.

4. A recombinant bacterium, characterized in that, It was constructed using Corynebacterium glutamicum MHZ-0112-8, with accession number CGMCC No.11941, as the starting strain. It expresses a protein mutant, or contains the coding gene of the protein mutant, wherein the protein mutant or its coding gene is as described in any one of claims 1-3.

5. A recombinant bacterium, characterized in that, It was constructed using Corynebacterium glutamicum MHZ-0912-6, with accession number CGMCC No.11942, as the starting strain. It expresses a protein mutant, or contains the coding gene of the protein mutant, wherein the protein mutant or its coding gene is as described in any one of claims 1-3.

6. A method for producing L-glutamic acid, characterized in that, It includes: The recombinant bacteria of claim 4 are cultured to produce, accumulate, and collect L-glutamic acid.

7. The method according to claim 6, characterized in that, The fermentation medium used includes the following components: glucose 50-60 g / L, ammonium sulfate 10-20 g / L, KH2PO4 0.5-1.5 g / L, MgSO4•7H2O 0.2-0.5 g / L, FeSO4•7H2O 0.05-0.15 mg / L, MnSO4•5H2O 0.8-1.2 mg / L, VB1 150-250 μg / L, biotin 250-350 μg / L, soybean hydrolysate 0.3-0.6 g / L, pH 7.2-7.5; Alternatively, the fermentation medium used may include the following components: glucose 15-25 g / L, corn steep liquor 15-25 g / L, betaine hydrochloride 0.1-0.3 g / L, K₂HPO₄ 6-8 g / L, MgSO₄•7H₂O 1-2 g / L, V B1 150-250 μg / L, VH 550-650 μg / L, FeSO4•7H2O 25-35 mg / L, MnSO4•H2O 25-35 mg / L, urea 0.4-0.7 g / L, pH 7.2-7.

5.

8. A method for producing lysine, characterized in that, It includes: The recombinant bacteria of claim 5 are cultured to produce, accumulate, and collect lysine.

9. The method according to claim 8, characterized in that, The fermentation medium used includes the following components: glucose 55-65 g / L, (NH4)2SO4 22-28 g / L, KH2PO4 1.5-2.5 g / L, MgSO4•7H2O 0.8-1.2 g / L, yeast extract 8-12 g / L, CaCO3 20-30 g / L, pH 6.8-7.2.

Citation Information

Patent Citations

  • Recombinant strain and application thereof

    CN105695383A

  • Recombinant strain, as well as preparation method and application thereof

    CN105734004A

  • Recombinant strain for modifying gene BBD29-14900 as well as construction method and application of recombinant strain

    CN112725253A

  • Microorganism capable of producing L-amino acid, and method for producing L-amino acid

    CN102177246A

  • Corynebacterium glutamicum for high-yield production of glutamic acid and application of corynebacterium glutamicum

    CN112322594A